Caspofungin for the treatment of candidaemia in patients with haematological malignancies

Livio Pagano, Luana Fianchi, R Fanci, A Candoni, Morena Caira, Brunella Posteraro, M Morselli, Cg Valentini, Giuliana Farina, Me Mitra, M Offidani, Maurizio Sanguinetti, Me Tosti, A Nosari, Giuseppe Leone, P. Viale

Research output: Contribution to journalArticle

8 Citations (Scopus)


This study was prospectively conducted in 11 haematology divisions over a 2-year period to evaluate the efficacy of caspofungin in 24 neutropenic patients with haematological malignancies (HM) and candidaemia. These patients had received chemotherapy for HM and were neutropenic (PNN < 0.5 x 10(9)/L) for a median of 12 days (2-41) before candidaemia. The patients received caspofungin for a median duration of 12 days (range 6-26), obtaining a favourable overall response of 58%. At 30 days, 11 patients had died (46%); candidaemia was responsible for mortality in six patients (25%). These results suggest that treatment of candidaemia with caspofungin in neutropenic HM was efficacious, as it is in non-haematological subgroups.
Original languageEnglish
Pages (from-to)298-301
Number of pages4
JournalClinical Microbiology and Infection
Publication statusPublished - 2010


  • Adult
  • Aged
  • Antifungal Agents
  • Antineoplastic Agents
  • Candidiasis
  • Drug Therapy
  • Echinocandins
  • Female
  • Fungemia
  • Hematologic Neoplasms
  • Humans
  • Male
  • Middle Aged
  • Neutropenia
  • Prospective Studies
  • Treatment Outcome
  • Young Adult


Dive into the research topics of 'Caspofungin for the treatment of candidaemia in patients with haematological malignancies'. Together they form a unique fingerprint.

Cite this